PBLS Parabilis Medicines, Inc. - Common Stock
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Aug 13, 2026PBLS Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
PBLS Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | PBLS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/B (MRQ) | 3.5 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Not enough fundamentals data to compute this ratio group yet.
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | PBLS | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.0 | · | · | · | |
| Current Ratio (MRQ) | 17.9 | · | · | · | |
| Long-Term Debt / Equity (MRQ) | 0.0 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $-2.12 | $0.08 | -2698.0% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
We don't have SEC filings for this ticker yet.
Income Statement
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Revenue | $148.0K | $0 | |
| R&D Expense | $39M | $30M | |
| SG&A Expense | $12M | $6M | |
| Operating Expenses | $51M | $37M | |
| Operating Income | $-51M | $-37M | |
| Other Non-op | $-2M | $2M | |
| Net Income | $-52M | $-35M | |
| EPS (Basic) | $-2.32 | $-22.28 | |
| EPS (Diluted) | $-2.32 | $-22.28 | |
| Shares (Basic) | 28,908,277 | 2,019,111 | |
| Shares (Diluted) | 28,908,277 | 2,019,111 | |
| EBITDA | $-51M | · |
Balance Sheet
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Cash & Equivalents | $1.09B | · | |
| Short-term Investments | $34M | · | |
| Prepaid Expense | $5M | · | |
| Current Assets | $1.13B | · | |
| PP&E (Net) | $7M | · | |
| PP&E (Gross) | $21M | · | |
| Accum. Depreciation | $14M | · | |
| Total Assets | $1.18B | · | |
| Accounts Payable | $19M | · | |
| Accrued Liabilities | $20M | · | |
| Short-term Debt | $5M | · | |
| Current Liabilities | $63M | · | |
| Capital Leases | $32M | · | |
| Total Liabilities | $128M | · | |
| Long-term Debt | $6M | · | |
| Total Debt | $11M | · | |
| Common Stock | $12.0K | · | |
| Paid-in Capital | $1.69B | · | |
| Retained Earnings | $-639M | · | |
| AOCI | $-18.0K | · | |
| Stockholders' Equity | $1.05B | · | |
| Liabilities + Equity | $1.18B | · | |
| Shares Outstanding | 121,938,652 | · |
Cash Flow
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| D&A | $600.0K | $200.0K |
Profitability
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Operating Margin | -34382.4% | · | |
| Net Margin | -35448.0% | · | |
| EBITDA Margin | -34382.4% | · | |
| ROA | -8.9% | · | |
| ROE | -10.0% | · |
Liquidity & Solvency
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Current Ratio | 17.9 | · | |
| Quick Ratio | 17.8 | · | |
| Debt / Equity | 0.0 | · | |
| LT Debt / Equity | 0.0 | · |
Efficiency
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Asset Turnover | 0.0 | · |
Per Share
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Book Value / Share | $8.59 | · | |
| Revenue / Share | $0.01 | · | |
| Cash / Share | $8.91 | · |
Valuation (TTM)
| Metric | Trend | Q2 2026 | Q2 2025 |
|---|---|---|---|
| Market Cap | $3.34B | · | |
| Enterprise Value | $2.23B | · | |
| P/B | 3.2 | · | |
| P / Tangible Book | 3.2 | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Not enough fundamentals data to build this statement yet.
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, RA Capital Healthcare Fund, L.P. | June 18, 2026 | 23.80% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 8 insiders · 0 officers · 8 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Craig Tendler | Director | Aug. 22, 2026 A | · | 0 | 0 | $0 |
| Alan Sebulsky | Director | June 15, 2026 P | 30,000 | 4 | 0 | $723,558 |
| Alexis Borisy | Director | June 11, 2026 C | 105,414 | 0 | 0 | $0 |
| Edward M Fitzgerald | Director | June 11, 2026 C | 14,688 | 0 | 0 | $0 |
| Jake Simson | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Barbara Weber | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Richard Klausner | Director | June 9, 2026 A | · | 0 | 0 | $0 |
| Krishna Yeshwant | Director | June 9, 2026 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 4 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
PBLS Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
4 analysts · 2026-10-03Mean target $41.75 +37.9%
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| PBLS | · | · | · | · | · | · |
| RLAY | $1.47B | -5.3 | 53.4% | -1800.6% | -44.9% | · |
| TNGX | $1.20B | -10.2 | 48.3% | -162.8% | -42.2% | · |
| VKTX | $4.04B | -11.0 | · | · | -47.3% | · |
| LEGN | · | -26.8 | · | · | -29.1% | · |
| VCYT | $3.34B | 51.3 | 16.0% | 12.8% | 5.2% | 70.1% |
| IDYA | $3.04B | -27.0 | 3024.4% | -52.0% | -11.5% | · |
| CELC | $4.81B | -26.3 | · | · | -244.3% | · |
| CDNA | $959M | -47.1 | 13.8% | -5.6% | -6.8% | · |
| ACAD | $4.55B | 11.6 | 11.9% | 36.5% | 38.1% | · |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.